Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4 Gynecologic 3 Lymphoid 2 Sarcoma 1 Other solid neoplasm 1 Gastrointestinal 1 Breast 1

Conditions

Interventions

Doxorubicin 44 Imatinib Mesylate 33 pembrolizumab 23 Cyclophosphamide 23 Sunitinib 22 Gemcitabine 22 Temozolomide 17 Irinotecan 14 Bevacizumab 14 Docetaxel 13 nilotinib 12 Trabectedin 12 ripretinib 11 pazopanib 11 olaratumab 10 fludarabine 10 eribulin 10 regorafenib 9 avapritinib 9 Fluorouracil 9 Carboplatin 9 Paclitaxel 8 Nivolumab 8 Ifosfamide 8 Ibandronic Acid 8 spartalizumab 7 anlotinib 7 Vincristine 7 Radiation 7 Ipilimumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × chiauranib × Sarcoma × Clear all

NCT05497843 2025-04-03

Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)

Chipscreen Biosciences, Ltd.

Phase 2 Completed

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡